As the global prevalence of chronic diseases continues to increase, investing in GLP-1 therapies offers a strategic opportunity to improve the lives of millions worldwide and promote long-term …

Patient safety is our top priority, and we are committed to supporting the active fight against falsified Novo Nordisk medicines and other illegal activity in the market.

At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions.

Novo Nordisk Press Release To see all the news please click on the button below.

These statements are based on current plans, estimates, opinions, views and projections. Although Novo Nordisk believes that the expectation reflected in such forward-looking …

Our pioneering discoveries produced today's breakthrough GLP-1 therapies and today we are relentlessly pursuing the next advances. Today our scientists continue to study how synthetic …

A major breakthrough that further expanded treatment options and reduced barriers, this innovative tablet eliminates the need for injections with GLP-1 – a welcome relief for many …

Injection pens and injection needles from Novo Nordisk for diabetes, obesity and growth hormone deficiency. See the types of insulin pens available here and learn how to use our insulin pens.

In 2024, the Therapeutics Goods Administration prohibited pharmacists in Australia from compounding GLP-1 RAs, including semaglutide. Novo Nordisk's testing shows that …

1. FlexPen ® is pre-filled with insulin or GLP-1 so you don't have to load it 2. The pen is colour-coded for easy identification 3. Doses are provided in one unit increments for insulin medicines …